[39] Burdett S, Boevé LM, Ingleby FC, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur Urol 2019;76(1):115-24.

[40] Dai B, Zhang S, Wan FN, et al. Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial. Eur Urol Oncol 2022;5(5):519-25.

[41] Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II Trial. J Clin Oncol 2018;36(5):446-53.

[42] Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 2020;6(5):650-9.

[43] Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomized, phase 2, open-label trial. Lancet 2019;393(10185):2051-8.

[44] Siva S, Bressel M, Murphy DG, et al. Stereotactic Abative Body Radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol 2018;74(4):455-62.

[45] Deek MP, Van der Eecken K, Sutera P, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol 2022;40(29):3377-82.

[46] Chmura SJ, Winter KA, Woodward WA, et al. NRG-BR002: a phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer. J Clin Oncol 2022;40(16_suppl). 1007-1007.

[47] Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 2020;383(11):1040-9.

[48] Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2020;382(23):2197-206.

[49] Smith MR, Saad F, Chowdhury S, et al. Apalutamide and overall survival in prostate cancer. Eur Urol 2021;79(1):150-8.

[50] Fallah J, Zhang L, Amatya A, et al. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. Lancet Oncol 2021;22(9):1230-9.

[51] Fendler WP, Weber M, Iravani A, et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 2019;25(24):7448-54.

[52] Malone S, Wallis CJD, Lee-Ying R, et al. Patterns of care for non-metastatic castration-resistant prostate cancer: a population-based study. BJUI Compass 2022;3(5):383-91.

[53] Jadvar H, Calais J, Fanti S, et al. Appropriate use criteria for prostate-specific membrane antigen PET Imaging. J Nucl Med 2022;63(1):59-68.

[54] Patel PH, Tunariu N, Levine DS, et al. Oligoprogression in metastatic, castrate-resistant prostate cancer-prevalence and current clinical practice. Front Oncol 2022;12:862995.

[55] Onal C, Kose F, Ozyigit G, et al. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment. Prostate 2021;81(9):543-52.

[56] Berghen C, Joniau S, Rans K, et al. Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial. BMC Cancer 2020;20(1):457.

[57] Triggiani L, Mazzola R, Magrini SM, et al. Metastasis-directed stereotactic radiotherapy for oligoprogessive castration-resistant prostate cancer: a multicenter study. World J Urol 2019;37(12):2631-7.

[58] Pan J, Wei Y, Zhang T, et al. Stereotactic radiotherapy for lesions detected via 68Ga-Prostate-specific membrane antigen and 18F-Fluorodexyglucose positron emission tomography/computed tomography in patients with nonmetastatic prostate cancer with early prostate-specific antigen progression on androgen deprivation therapy: a prospective single-center study. Eur Urol Oncol 2022;5(4):420-7.

[59] Hussain M, Mateo J, Fizazi K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 2020;383(24):2345-57.

[60] Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 2020;38(32):3763-72.

[61] Clarke NW, Armstrong AJ, Thiery-Vuillemin, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid 2022;1(9).

[62] Chi NK, Rathkopf DE, Smith MR, et al. Phase 3 MAGNITUDE study: first results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. J Clin Oncol 2022;40(6_suppl). 12-12.

[63] Armstrong AJ, Saad F, Thiery-Vuillemin A, et al. Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial. Ann Oncol 2022;33(Supplement 7):S1168. ISSN 0923-7534.

[64] Sartor O, Fougère C, Essler M, et al. 177Lu-prostate-specific membrane antigen ligand after 223Ra treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience [published correction appears in J Nucl Med. 2022 Jul;63(7):100-1000]. J Nucl Med 2022;63(3):410-4.

[65] Assi T, Rassy E, Farhat F, Kattan C, Kattan J. Docetaxel re-challenge in patients with metastatic prostate cancer: a comprehensive review. Oncol Res Treat 2020;43(6):299-306.

[66] Wu YM, Cieślik M, Lonigro RJ, et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate. Cancer Cell 2018;173(7):1770-82. e14.

[67] Reimers MA, Yip SM, Zhang L, et al. Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer. Eur Urol 2020;77(3):333-41.

[68] Antonarakis ES. Cyclin-dependent kinase 12, immunity, and prostate cancer. N Engl J Med 2018;379(11):1087-9.

[69] Antonarakis ES, Isaacsson Velho P, Fu W, et al. CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase inhibitors, and PD-1 inhibitors. JCO Precis Oncol 2020;4:370-81.

[70] Hempelmann JA, Lockwood CM, Konnick EQ, et al. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. J Immunother Cancer 2018;6(1):29.

[71] Graham LS, Montgomery B, Cheng HH, et al. Mismatch repair deficiency in metastatic prostate cancer: response to PD-1 blockade and standard therapies. PLoS One 2020;15(5):e0233260.

[72] Barata P, Agarwal N, Nussenzveig R, et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J Immunother Cancer 2020;8(2):e001065.

[73] Antonarakis ES, Shaukat F, Isaacsson Velho P, et al. Clinical features and therapeutic outcomes in men with advanced prostate cancer and dna mismatch repair gene mutations. Eur Urol 2019;75(3):378-82.
[74] Sena LA, Fountain J, Isaacsson Velho P, et al. Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer. Oncologist 2021;26(2):e270–8.

[75] Graf RP, Fisher V, Weberpals J, et al. Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer [published correction appears in JAMA Netw Open. 2022 May 2;5(5):e2213901]. JAMA Netw Open 2022;5(3):e225394.

[76] Sokol ES, Jin DX, Fine A, et al. PARP inhibitor insensitivity to BRCA1/2 monoallelic mutations in microsatellite instability-high cancers. JCO Precis Oncol 2022;6:e2100531.

[77] Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385(12):1091–103.

[78] Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 2021;397(10276):797–804.

[79] Bryce AH, Alumkal JJ, Armstrong A, et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis 2017;20(2):221–7.

[80] Saad F, Sternberg CN, Efstathiou E, et al. Prostate-specific antigen progression in enzalutamide-treated men with nonmetastatic castration-resistant prostate cancer: any rise in prostate-specific antigen may require closer monitoring. Eur Urol 2020;78(6):847–53.

[81] Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group. J Clin Oncol 2016;34(12):1402–18.

[82] Gafita A, Rauscher I, Weber M, et al. Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (recip 1.0): an international multicenter study. J Nucl Med 2022;63(11):1651–8.

[83] Wang Y, Galante JR, Haroon A, et al. The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer. Nat Rev Urol 2022;19(8):475–93.

[84] Fanti S, Goffin K, Hadaschik BA, et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging 2021;48(2):469–76.

[85] Kuten J, Sarid D, Yossepowitch O, Mabjeesh NJ, Even-Sapir E. [68Ga]Ga-PSMA-11 PET/CT for monitoring response to

treatment in metastatic prostate cancer: is there any added value over standard follow-up? EJNMMI Res 2019;9(1):84.

[86] Kuo P, Hesterman J, Rahbar K, et al. [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION sub-study. J Clin Oncol 2022;40(16_suppl). 5002-5002.

[87] Buteau JP, Martin AJ, Emmett L, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol 2022;23(11):1389–97.

[88] Beltran H, Tomlins S, Aparicio A, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 2014;20(11):2846–50.

[89] Labrecque MP, Alumkal JJ, Coleman IM, Nelson PS, Morrissey C. The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches. Endocr Relat Cancer 2021;28(8):T51–66.

[90] Mu P, Zhang Z, Benelli M, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 2017;355(6320):84–8.

[91] Ku SY, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and anti-androgen resistance. Science 2017;355(6320):78–83.

[92] Bluemn EG, Coleman IM, Lucas JM, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 2017;32(4):474–89. e6.

[93] Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial [published correction appears in Lancet Oncol. 2020 Jan;21(1):e14]. Lancet Oncol 2019;20(10):1432–43.

[94] Vogl UM, Beer TM, Davis ID, et al. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Eur J Cancer 2022;160:24–60.

[95] Van Wambeke S, Vera-Badillo FE, Gyawali B. Controlling the control arm in metastatic castration-resistant prostate cancer trials: best standard of care or the minimum standard of care? J Clin Oncol 2022;40(14):1518–21.

[96] Ardolino LC, Dear R, Armstrong AJ, Gillessen S, Joshua AM. Clinical trials for metastatic castrate-resistant prostate cancer-who is looking after the control patients? Questions for the future. Ann Oncol 2022;33(6):574–7.